Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026)

Sarepta Therapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $394.8 million for Q1 2026.

• On a quarterly basis, Receivables - Net fell 40.12% year-over-year to $394.8 million in Q1 2026; TTM through Mar 2026 was $394.8 million, a 40.12% decrease from a year earlier, with the FY2025 full-year figure at $398.2 million, down 33.85% from the prior year.
• Receivables - Net retreated to $394.8 million in Q1 2026 per SRPT's latest filing, from $398.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $659.4 million in Q1 2025 and bottomed at $178.2 million in Q1 2022.
• The 5-year median for Receivables - Net is $378.8 million (2024), against an average of $360.5 million.
• Across the five-year window, Receivables - Net soared 86.53% in 2023 and tumbled 40.12% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $214.6 million in 2022, then surged by 86.53% to $400.3 million in 2023, then soared by 50.38% to $602.0 million in 2024, then slumped by 33.85% to $398.2 million in 2025, then slipped by 0.86% to $394.8 million in 2026.
• Per Business Quant, the three latest SRPT Receivables - Net figures stand at $394.8 million (Q1 2026), $398.2 million (Q4 2025), and $395.7 million (Q3 2025).